A recent study reports on drug clearance in newborn babies after in utero exposure to anti-TNF antibodies, infliximab and adalimumab. As women with IBD are increasingly exposed to these drugs due to changing treatment paradigms and earlier diagnosis, this commentary explores these clinically important results.

, , ,
doi.org/10.1038/nrgastro.2016.94, hdl.handle.net/1765/93321
Nature Reviews Gastroenterology and Hepatology
Department of Gastroenterology & Hepatology

van der Woude, J., & Kanis, S. (2016). IBD: exposure to anti-TNF agents in utero: controlling health risks. Nature Reviews Gastroenterology and Hepatology, 13(7), 387–388. doi:10.1038/nrgastro.2016.94